Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Licensing > BDA202204

Trop2 ADC

Discovery
Preclinical
IND
PH1
PH2
PH3
BLA Filing
Active
  • Project profile
    Project name: Trop2 ADC
    Indications: Gastric cancer,Pancreatic cancer
    Research phase: IND
    Cooperation demands: License-out or co-development
  • Highlights

    1. Clear MoA. Trop2 is highly expressed in a variety of tumors, such as gastric cancer, pancreatic cancer, etc., and can promote tumor cell proliferation, invasion, metastasis, and other processes. Its high expression is closely related to shortened survival and poor prognosis of tumor patients.



    2. Significant preclinical efficacy and less toxic & side effects.

    a) The monotherapy inhibits pancreatic cancer tumor growth significantly.



    The monotherapy inhibits pancreatic cancer tumor growth significantly

    b) The patented VK linker enhances the tissue penetration of payload and expands the therapeutic window, this asset has at least 400 times therapeutic window.



    The patented VK linker enhances the tissue penetration of payload and expands the therapeutic window, this asset has at least 400 times therapeutic window.

    c) Excellent “bystander effects”



    Excellent “bystander effects ”



    3. Global competitiveness: The patented VK linker enables better tumor invasion in pancreatic and gastric cancers. Right now, no ADC is satisfactory in treating these two cancers.



    4. Good market potential:It is estimated that the number of new pancreatic cancer patients worldwide will reach 486,300 in 2028, and the pancreatic cancer drug market will reach US$4.1 billion; the global new gastric cancer patients will reach 1.1 million, and the gastric cancer drug market will reach US$4.4 billion.

  • Project Introduction

    1. Asset type: Trop2 ADC

    2. Indication: “hard-to-treat” solid tumors (pancreatic, gastric, etc)

    3. Research phase: Pre-IND preparation

    3. Cooperation demands: License-out or co-development

    4. Research progress:
          1) Completed preclinical development and ready for IND filing.
          2) The patented VK linker enhances the tissue penetration of payload and expands the therapeutic window.
          3) The safety test has been completed, and there are no obvious toxic and side effects.

Comments (0)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message